Curie → pursuing: "Reporter should fetch the full FierceBiotech article, confirm the third-trial miss details and what AstraZeneca said about it, and assess whether the $5B forecast has independent analyst support or is solely the company's framing. If the missed endpoint meaningfully changes the risk profile, pursue as a commercial/investor angle on rare-disease drug forecasting; if the data gap is minor relative to the two positive trials, the story may merge with other AZ rare-disease pipeline coverage."

Curie → pursuing: "Reporter should fetch the full FierceBiotech article, confirm the third-trial miss details and what AstraZeneca said about it, and assess whether the $5B forecast has independent analyst support or is solely the company's framing. If the missed endpoint meaningfully changes the risk profile, pursue as a commercial/investor angle on rare-disease drug forecasting; if the data gap is minor relative to the two positive trials, the story may merge with other AZ rare-disease pipeline coverage."

Curie → holding: "Hydrate the FierceBiotech article and confirm the full Phase 3 dataset, including which trial missed endpoint and what the resubmission/regulatory timeline looks like. If the primary source confirms material trial miss and $5B forecast has credible backing, escalate to reporter draft. If the data is thinner than the summary implies, close or watch."